
**CLAIMS:**

1. Use of a compound of general formula **I**



(**I**)

wherein X is selected from O and NH;

Y is selected from CO and –COCH($CH_3$)CO-;

each n and p is independently selected from 0 and 1, and q is selected from 0, 1 and 2;

each $R_1$, $R_3$, $R_5$, $R_9$, $R_{11}$, and $R_{15}$ is independently selected from hydrogen, substituted or unsubstituted $C_1$-$C_6$ alkyl, substituted or unsubstituted $C_2$-$C_6$ alkenyl, and substituted or unsubstituted $C_2$-$C_6$ alkynyl;

$R_2$ is selected from hydrogen, $COR_a$, $COOR_a$, substituted or unsubstituted $C_1$-$C_6$ alkyl, substituted or unsubstituted $C_2$-$C_6$ alkenyl, and substituted or unsubstituted $C_2$-$C_6$ alkynyl;

each $R_4$, $R_8$, $R_{10}$, $R_{12}$, and $R_{16}$ is independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl;

each $R_7$ and $R_{13}$ is independently selected from hydrogen, substituted or unsubstituted $C_1$-$C_6$ alkyl, substituted or unsubstituted $C_2$-$C_6$ alkenyl, and substituted or unsubstituted $C_2$-$C_6$ alkynyl; each $R_6$ and $R_{14}$ is independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; or $R_6$ and $R_7$ and/or $R_{13}$ and $R_{14}$ together with the corresponding N atom and C atom to which they are attached may form a substituted or unsubstituted heterocyclic group;

$R_{17}$ is selected from hydrogen, $COR_a$, $COOR_a$, $CONHR_b$, $COSR_c$, $(C{=}NR_b)OR_a$, $(C{=}NR_b)NHR_b$, $(C{=}NR_b)SR_c$, $(C{=}S)OR_a$, $(C{=}S)NHR_b$, $(C{=}S)SR_c$, $SO_2R_c$, $SO_3R_c$, substituted or unsubstituted $C_1$-$C_{12}$ alkyl, substituted or unsubstituted $C_2$-$C_{12}$ alkenyl, substituted or unsubstituted $C_2$-$C_{12}$ alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group, with the proviso that when n, p, and q are 0 then $R_{17}$ is not hydrogen; and

each $R_a$, $R_b$, and $R_c$ is independently selected from hydrogen, substituted or unsubstituted $C_1$-$C_{12}$ alkyl, substituted or unsubstituted $C_2$-$C_{12}$ alkenyl, substituted or unsubstituted $C_2$-$C_{12}$ alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group;

or a pharmaceutically acceptable salt or stereoisomer thereof, in the manufacture of a medicament for the treatment of an autoimmune condition.

2. The use of claim 1, wherein the autoimmune condition is caused by the activation of one or more Toll-like receptor (TLR).

3. The use of claim 1, wherein the autoimmune condition is characterised by increased signalling through at least one or more Toll-like receptor (TLR).

4. The use of claim 1, wherein the autoimmune condition is characterised by increased levels of at least one pro-inflammatory cytokines.

5. The use of any of claims 1 to 4, wherein the autoimmune condition is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), scleroderma, Sjögren's syndrome, autoimmune myocarditis, type 1 diabetes, and atherosclerosis.

6. The use of claim 5, wherein the autoimmune condition is RA.

7. The use according to any one of claims 1 to 6, wherein $R_3$ and $R_4$ are independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_3$ is isopropyl and $R_4$ is hydrogen.

8. The use according to any one of claims 1 to 7, of general formula **II**, wherein $R_3$ and $R_4$ are methyl.

9. The use according to any preceding claim, wherein $R_{11}$ is selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_{11}$ is methyl or isobutyl.

10. The use according to any preceding claim, of general formula **III** wherein $R_{11}$ is methyl and n=1.

11. The use according to any preceding claim, wherein $R_1$, $R_5$, $R_9$, and $R_{15}$ are independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_1$ is selected from sec-butyl and isopropyl, $R_5$ is isobutyl, $R_9$ is p-methoxybenzyl, and $R_{15}$ is selected from methyl and benzyl.

12. The use according to any preceding claim, wherein $R_8$, $R_{10}$, $R_{12}$, and $R_{16}$ are independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_8$, $R_{10}$ and $R_{12}$ are methyl, and $R_{16}$ is hydrogen.

13. The use according to any preceding claim, wherein $R_6$ and $R_{14}$ are independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_6$ is selected from hydrogen and methyl, and $R_{14}$ is hydrogen.

14. The use according to any preceding claim, wherein $R_7$ and $R_{13}$ are independently selected from hydrogen and substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_7$ is methyl and $R_{13}$ is selected from hydrogen, methyl, isopropyl, isobutyl, and 3-amino-3-oxopropyl.

15. The use according to any of claims 1 to 12, wherein $R_6$ and $R_7$ and/or $R_{13}$ and $R_{14}$ together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted pyrrolidine group.

16. The use according to any preceding claim, wherein $R_2$ is selected from hydrogen, substituted or unsubstituted $C_1$-$C_6$ alkyl, and $COR_a$, and wherein $R_a$ is a substituted or unsubstituted $C_1$-$C_6$ alkyl; preferably wherein $R_2$ is hydrogen.

17. The use according to any preceding claim, wherein $R_{17}$ is selected from hydrogen, $COR_a$,

$COOR_a$, $CONHR_b$, $(C=S)NHR_b$, and $SO_2R_c$, and wherein each $R_a$, $R_b$, and $R_c$ is independently selected from substituted or unsubstituted $C_1$-$C_6$ alkyl, substituted or unsubstituted $C_2$-$C_6$ alkenyl, substituted or unsubstituted $C_2$-$C_6$ alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group; preferably wherein $R_{17}$ is selected from hydrogen, COObenzyl, COBenzo[b]thiophen-2-yl, $SO_2$(p-methylphenyl), $COCOCH_3$ and $COOC(CH_3)_3$.






18. The use according to any preceding claim, wherein X is NH.


19. The use according to any of claims 1 to 17, wherein X is O.

20. The use according to any preceding claim wherein Y is CO.


21. The use according to any of claims 1 to 19, wherein Y is –$COCH(CH_3)CO$-.

22. The use according to any one of claims 1 to 6, having the following structure:



,

,

,

,

,





,





,




5 , and




, or




,

or pharmaceutically acceptable salts or stereoisomers thereof.

23. The use according to any one of claims 1 to 6, wherein the compound is PLD, or pharmaceutically acceptable salts or stereoisomers thereof.

24. The use according to any one of claims 1 to 6, wherein the compound is didemninB, or pharmaceutically acceptable salts or stereoisomers thereof.

25. The use according to any one of claims 1 to 6, wherein the compound is PLD.

26. The use according to any one of claims 1 to 6, wherein the compound is Didemnin B.

27. A kit comprising the compound as defined in any of claims 1 to 26, together with instructions for treating an autoimmune condition.